Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Daniel Demetri, M.D.

Co-Author

This page shows the publications co-authored by George Demetri and Adrian Marino Enriquez.
Connection Strength

0.604
  1. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014 Apr 03; 33(14):1872-6.
    View in: PubMed
    Score: 0.141
  2. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020; 4:79-90.
    View in: PubMed
    Score: 0.056
  3. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32.
    View in: PubMed
    Score: 0.056
  4. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
    View in: PubMed
    Score: 0.055
  5. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019 09; 38(39):6615-6629.
    View in: PubMed
    Score: 0.054
  6. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620.
    View in: PubMed
    Score: 0.053
  7. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017 03 08; 8:14674.
    View in: PubMed
    Score: 0.046
  8. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.038
  9. KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6.
    View in: PubMed
    Score: 0.038
  10. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.036
  11. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.